Unichem's US subsidiary voluntarily recalled Buspirone Hydrochloride 5mg tablets due to an out-of-specification assay result found during stability testing.
The recall involves 500-count bottles distributed in the USA, with no adverse event reports received to date.
The company emphasized its highest priority on patient safety and maintaining product quality in its manufacturing processes.
Disclosure made under SEBI Listing Regulations (Regulation 30) to inform stock exchanges of this material event.